An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses
An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses
复制标题
DOI：
10.1016/j.vaccine.2007.08.020
复制
发表时间：
2007-10-16
期刊：
影响因子：
5.5
通讯作者：
Inchauspe, G.
中科院分区：
文献类型：
--
作者：
Fournillier, A.;Gerossier, E.;Inchauspe, G.
我们在hla - I类转基因小鼠模型中设计并评估了一种基于丙型肝炎病毒（HCV） T细胞的MVA载体疫苗，该疫苗表达三种已知的病毒抗原，这些病毒抗原是CD8+和CD4+介导的有效应答的靶标。加速（基于3周的）疫苗接种诱导特异性CD8+ T细胞具有两种效应功能（体外和体内的细胞溶解活性和IFN γ的产生）以及识别所有三种疫苗抗原的特异性CD4+ T细胞。反应是持久的（6个月），通过第四次MVA疫苗接种可以增强，并且在基于替代李斯特菌的攻击试验中证明了体内交叉反应。这种候选疫苗现已进入临床试验阶段。(c) 2007 Elsevier Ltd.版权所有。
We designed and evaluated in HLA-class I transgenic mouse models a hepatitis C virus (HCV) T cell-based MVA vectored vaccine expressing three viral antigens known to be targets of potent CD8+- and CD4+-mediated responses. An accelerated (3 week-based) vaccination induced specific CD8+ T cells harboring two effector functions (cytolytic activity - both in vitro and in vivo - and production of IFN gamma) as well as specific CD4+ T cells recognizing all three vaccine antigens. Responses were long lasting (6 months), boostable by a fourth MVA vaccination and in vivo cross-reactive as demonstrated in a surrogate Listeria-based challenge assay. This candidate vaccine has now moved into clinical trials. (c) 2007 Elsevier Ltd. All rights reserved.